TY - JOUR
T1 - The changes in kynurenine metabolites induced by rTMS in treatment-resistant depression
T2 - A pilot study
AU - Tateishi, Hiroshi
AU - Setoyama, Daiki
AU - Kang, Dongchon
AU - Matsushima, Jun
AU - Kojima, Ryohei
AU - Fujii, Yuka
AU - Mawatari, Seiji
AU - Kikuchi, Jun
AU - Sakemura, Yuta
AU - Fukuchi, Junko
AU - Shiraishi, Takumi
AU - Maekawa, Toshihiko
AU - Kato, Takahiro A.
AU - Asami, Toyoko
AU - Mizoguchi, Yoshito
AU - Monji, Akira
N1 - Funding Information:
This work was supported in part by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS KAKENHI Grant Number 17K10307 to H.T. and 18K07417 to D.S.)
Publisher Copyright:
© 2021
PY - 2021/6
Y1 - 2021/6
N2 - Background: Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive brain stimulation technique that is considered a valuable and promising technique for improving depressive symptoms in treatment-resistant depression (TRD). However, the exact mechanism by which rTMS ameliorates depressive symptoms remains to be clarified. Objective: The aim of the present study was to analyzed the changes in metabolites of patients with TRD in the rTMS treatment, especially focusing on the kynurenine (KYN) pathway. Methods: Thirteen participants with TRD were enrolled in a high-frequency (10 Hz) rTMS study. Cognitive function, depressive symptoms and the concentration of plasma tryptophan (TRP) metabolites were measured at baseline and at the endpoint of rTMS treatment. Results: rTMS treatment significantly improved depressive symptom scores and some subscales of cognitive dysfunction. The present study has demonstrated that rTMS treatment significantly increased plasma TRP levels and significantly decreased plasma serotonin levels, while plasma KYN and kynurenic acid level as well as KYN/TRP ratio remained unchanged. Conclusions: This is the first metabolomic study of patients with TRD undergoing rTMS treatment. To validate the present results, it is necessary to increase the number of cases including controls, use a sample of cerebrospinal fluid, and measure blood concentration over time in the course of rTMS treatment.
AB - Background: Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive brain stimulation technique that is considered a valuable and promising technique for improving depressive symptoms in treatment-resistant depression (TRD). However, the exact mechanism by which rTMS ameliorates depressive symptoms remains to be clarified. Objective: The aim of the present study was to analyzed the changes in metabolites of patients with TRD in the rTMS treatment, especially focusing on the kynurenine (KYN) pathway. Methods: Thirteen participants with TRD were enrolled in a high-frequency (10 Hz) rTMS study. Cognitive function, depressive symptoms and the concentration of plasma tryptophan (TRP) metabolites were measured at baseline and at the endpoint of rTMS treatment. Results: rTMS treatment significantly improved depressive symptom scores and some subscales of cognitive dysfunction. The present study has demonstrated that rTMS treatment significantly increased plasma TRP levels and significantly decreased plasma serotonin levels, while plasma KYN and kynurenic acid level as well as KYN/TRP ratio remained unchanged. Conclusions: This is the first metabolomic study of patients with TRD undergoing rTMS treatment. To validate the present results, it is necessary to increase the number of cases including controls, use a sample of cerebrospinal fluid, and measure blood concentration over time in the course of rTMS treatment.
UR - http://www.scopus.com/inward/record.url?scp=85104077313&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85104077313&partnerID=8YFLogxK
U2 - 10.1016/j.jpsychires.2021.04.009
DO - 10.1016/j.jpsychires.2021.04.009
M3 - Article
C2 - 33865168
AN - SCOPUS:85104077313
SN - 0022-3956
VL - 138
SP - 194
EP - 199
JO - Journal of Psychiatric Research
JF - Journal of Psychiatric Research
ER -
